Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics filings provide 7 years of Non-Current Assets readings, the most recent being $22.6 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 16.32% to $22.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.5 million, a 3.78% decrease, with the full-year FY2025 number at $22.6 million, down 16.32% from a year prior.
  • Non-Current Assets hit $22.6 million in Q4 2025 for Keros Therapeutics, down from $23.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $27.2 million in Q3 2024 to a low of $1.7 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $22.1 million (2023), compared with a mean of $16.5 million.
  • Biggest five-year swings in Non-Current Assets: surged 466.39% in 2023 and later dropped 16.32% in 2025.
  • Keros Therapeutics' Non-Current Assets stood at $3.8 million in 2021, then surged by 451.4% to $21.0 million in 2022, then rose by 8.18% to $22.7 million in 2023, then increased by 18.74% to $27.0 million in 2024, then dropped by 16.32% to $22.6 million in 2025.
  • The last three reported values for Non-Current Assets were $22.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.4 million (Q2 2025) per Business Quant data.